...
首页> 外文期刊>Carcinogenesis >Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
【24h】

Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.

机译:过氧化物酶体增殖物激活受体β/δ(PPARbeta / delta)的配体激活和环氧合酶2(COX2)的抑制通过独立的信号传导机制减弱结肠癌的发生。

获取原文
获取原文并翻译 | 示例
           

摘要

Cyclooxygenase (COX) 2-derived prostaglandin E(2) (PGE(2)) promotes colorectal carcinoma growth and invasion, and inhibition of COX2 by non-steroidal anti-inflammatory drugs is known to inhibit these processes. There is controversy regarding the effect of ligand activation of peroxisome proliferator-activated receptor (PPAR)-beta/delta on colon carcinogenesis, although collective evidence from independent laboratories suggest that ligand activation of PPARbeta/delta leads to the induction of terminal differentiation coupled with inhibition of cell growth in a variety of models. The present study examined the hypothesis that ligand activation of PPARbeta/delta and inhibition of COX2 attenuate colon cancer through independent mechanisms and that combining these two mechanisms will enhance this inhibition. Colon cancer was induced by administering azoxymethane to wild-type and PPARbeta/delta-null mice. Cohorts of mice were treated with GW0742 (a PPARbeta/delta ligand), nimesulide (a COX2 inhibitor) or a combination of GW0742 and nimesulide. Inhibition of COX2 by nimesulide attenuated colon cancer and ligand activation of PPARbeta/delta by GW0742 had inhibitory effects. However, the combined treatment of GW0742 and nimesulide did not cause an enhancement in the attenuation of colon cancer. Mechanistically, the effects of these compounds occurred through independent mechanisms as increased levels of differentiation markers as a result of ligand activation of PPARbeta/delta were not found with COX2 inhibition, and a reduction in PGE(2) levels resulting from COX2 inhibition was not observed in response to ligand activation of PPARbeta/delta. Results from these studies effectively dissociate COX2 inhibition and PPARbeta/delta activity during colon carcinogenesis.
机译:环氧合酶(COX)2衍生的前列腺素E(2)(PGE(2))促进结直肠癌的生长和侵袭,已知非甾体抗炎药对COX2的抑制作用可抑制这些过程。关于过氧化物酶体增殖物激活受体(PPAR)-β/δ的配体活化对结肠癌发生作用的争论尚存争议,尽管来自独立实验室的集体证据表明,PPARbeta /δ的配体活化导致诱导终末分化并伴有抑制作用。各种模型中的细胞生长本研究检验了以下假设:配体激活PPARbeta / delta和抑制COX2通过独立的机制减弱了结肠癌,并且将这两种机制结合起来将增强这种抑制作用。通过对野生型和PPARbeta / delta-null小鼠施用甲氧甲烷来诱导结肠癌。用GW0742(PPARbeta /δ配体),尼美舒利(COX2抑制剂)或GW0742和尼美舒利的组合治疗小鼠。尼美舒利减缓结肠癌对COX2的抑制和GW0742对PPARbeta /δ的配体活化具有抑制作用。但是,GW0742和尼美舒利的联合治疗并未引起结肠癌衰减的增强。从机理上讲,这些化合物的作用是通过独立的机制发生的,因为未发现COX2抑制导致PPARbeta /δ的配体活化导致分化标志物水平升高,并且未观察到COX2抑制导致PGE(2)水平降低响应PPARbeta / delta的配体活化。这些研究的结果有效消除了结肠癌发生过程中COX2抑制作用和PPARbeta /δ活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号